$7.08
3.28%
Nasdaq, Apr 21, 08:15 pm CET
ISIN
US45782T1051
Symbol
INMB
Sector
Industry

Inmune Bio, Inc. Stock price

$7.32
-0.35 4.56% 1M
+2.32 46.40% 6M
+2.65 56.75% YTD
-1.11 13.17% 1Y
-0.16 2.14% 3Y
+2.93 66.74% 5Y
-0.67 8.39% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.01 0.14%
ISIN
US45782T1051
Symbol
INMB
Sector
Industry

Key metrics

Market capitalization $167.85m
Enterprise Value $147.31m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 14,731.00
P/S ratio (TTM) P/S ratio 16,785.00
P/B ratio (TTM) P/B ratio 5.08
Revenue growth (TTM) Revenue growth -90.97%
Revenue (TTM) Revenue $10.00k
EBIT (operating result TTM) EBIT $-42.64m
Free Cash Flow (TTM) Free Cash Flow $-33.36m
Cash position $20.92m
EPS (TTM) EPS $-2.13
P/E forward negative
Short interest 32.85%
Show more

Is Inmune Bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Inmune Bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Inmune Bio, Inc. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Inmune Bio, Inc. forecast:

Buy
100%

Financial data from Inmune Bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.01 0.01
94% 94%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.48 9.48
1% 1%
94,800%
- Research and Development Expense 33 33
64% 64%
331,700%
-43 -43
43% 43%
-426,400%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -43 -43
43% 43%
-426,350%
Net Profit -42 -42
40% 40%
-420,800%

In millions USD.

Don't miss a Thing! We will send you all news about Inmune Bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inmune Bio, Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and Gene Therapy Catapult (CGT Catapult) to establish large-scale, commercial-ready manufacturing for its cell therapy platforms. CGT Catapult is an...
Neutral
Seeking Alpha
25 days ago
INmune Bio, Inc. (NASDAQ:INMB ) Q4 2024 Results Conference Call March 27, 2025 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Mark Lowdell - Chief Scientific Officer Christopher Barnum - Head of Neuroscience Conference Call Participants George Farmer - Scotiabank Thomas Shrader - BTIG Denis Reznik - Raymond James Elemer Piros - Rodman James Molloy - Alliance Gl...
Neutral
GlobeNewsWire
25 days ago
BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update.
More Inmune Bio, Inc. News

Company Profile

INmune Bio, Inc. focuses on controlling components of the immune system to activate an immune response against cancer and Alzheimer's disease. Its product pipeline INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer, and LIVNATE. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.

Head office United States
CEO Raymond Tesi
Employees 22
Founded 2015
Website www.inmunebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today